(38) discovered that CD133 could also significantly increase the transcriptional level of the glutamate-aspartate transporter SLC1A3 in CD133+ thyroid cancer cells by triggering the NF-κB signaling pathway. This evidence concerns the gene NFKB1 and thyroid gland carcinoma.